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The molecular mechanisms linking the stress of un-
folded proteins in the endoplasmic reticulum (ER
stress) to glucose intolerance in obese animals are
poorly understood. In this study, enforced expres-
sion of a translation initiation factor 2a (eIF2a)-spe-
cific phosphatase, GADD34, was used to selectively
compromise signaling in the eIF2(aP)-dependent
arm of the ER unfolded protein response in liver of
transgenicmice. The transgene resulted in lower liver
glycogen levels and susceptibility to fasting hypogly-
cemia in lean mice and glucose tolerance and dimin-
ished hepatosteatosis in animals fed a high-fat diet.
Attenuated eIF2(aP) correlated with lower expres-
sion of the adipogenic nuclear receptor PPARg and
its upstream regulators, the transcription factors
C/EBPa and C/EBPb, in transgenic mouse liver,
whereas eIF2a phosphorylation promoted C/EBP
translation in cultured cells and primary hepatocytes.
These observations suggest that eIF2(aP)-mediated
translation of key hepatic transcriptional regulators
of intermediary metabolism contributes to the detri-
mental consequences of nutrient excess.
INTRODUCTION
Eukaryotic cells respond to fluctuations in the load of unfolded
proteins in the endoplasmic reticulum (ER) by an unfolded
protein response (UPR). The oldest arm of the UPR, which
is conserved in all eukaryotes, is mediated by IRE1, an ER
stress-regulated kinase/endoribonuclease that signals through
a transcription factor, XBP-1 (Hac1p in yeast), to activate UPR
target genes. In animals, XBP-1 is joined by ATF6, a transcription
factor that senses ER stress directly, to activate genes that en-
hance cells’ ability to copewith the load of unfolded proteins fac-
ing their ER (reviewed in Schroder and Kaufman, 2005; Bernales
et al., 2006). These transcriptional events are complemented by
a third arm of the UPR mediated by PERK, an ER-localized520 Cell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc.stress-activated kinasewhose only known substrate is the a sub-
unit of translation initiation factor 2 (eIF2a). Phosphorylation of
eIF2a on serine 51 inhibits the guanine nucleotide exchange
factor for eIF2 and reduces rates of translation initiation. The
consequent repression of protein synthesis diminishes the load
of unfolded proteins entering the ER and conserves ATP and
amino acids in ER-stressed cells. eIF2(aP) also activates gene
expression, which is accounted for, in part, by the translational
upregulation of the transcription factor ATF4 (reviewed in Ron
and Harding, 2007).
Earlier studies emphasized the UPR’s role in maintaining
homeostasis of the protein-folding environment in the ER lumen,
and its physiological significance was sought in the context
of cellular adaptation to the stress posed by unfolded and mis-
folded ER proteins. The phenotype of mutations in components
of the UPR is certainly consistent with this notion—knockout of
IRE1, XBP-1, ATF6, and PERK all reduce the ability of cells to
cope with ER stress (Delepine et al., 2000; Harding et al., 2001;
Shen et al., 2001; Zhang et al., 2002; Lee et al., 2005; Wu
et al., 2007; Yamamoto et al., 2007). However, accrued evidence
now suggests that ER stress and the response to it modulate
mammalian physiology in ways that cannot be explained simply
by the aforementioned cell-autonomous processes.
In addition to imparting hypersensitivity to ER stress, a homo-
zygous Eif2aS51A mutation (which abolishes regulatory phos-
phorylation of eIF2a) blocks hepatic glucose production in neo-
natal mice (Scheuner et al., 2001). By contrast, heterozygosity
for the same Eif2aS51A mutation disposes adult mice to obesity,
insulin resistance, and glucose intolerance (Scheuner et al.,
2005). Obesity promotes ER stress, presumably by increasing
the load of unfolded proteins in the ER, which is detected as en-
hanced UPR signaling in liver and fat (Ozcan et al., 2004; Naka-
tani et al., 2005). Importantly, compromised signaling in the UPR
by a partial loss-of-function mutation in XBP-1 (which further in-
creases the level of ER stress) or a mutation in the ER chaperone
ORP150 increases insulin resistance in obesemice (Ozcan et al.,
2004; Nakatani et al., 2005), whereas chemical chaperones or
ORP150 overexpression that reduces the level of ER stress sub-
stantially reverse the insulin resistance and glucose intolerance
of obese mice (Ozawa et al., 2005; Ozcan et al., 2006). These
studies imply that ER stress, or aspects of the response to it,
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simply attributed to variation in survival of secretory cells.
Several kinases phosphorylate eIF2a to activate adownstream
gene expression program that we refer to as the integrated
stress response (ISR) (Harding et al., 2003). In yeast, a GCN2-
mediated eIF2(aP)-dependent transcriptional program responds
to diverse metabolic perturbations (Hinnebusch and Natarajan,
2002), and the homologous mammalian eIF2a kinase is also im-
plicated in metabolic regulation (Hao et al., 2005; Maurin et al.,
2005; Guo and Cavener, 2007). These observations suggest
that links between metabolic regulation and eIF2a phosphoryla-
tion are conserved and might contribute to the physiological
response to ER stress in mammals. Here we have focused on
eIF2(aP) signaling in the liver, a key organ for intermediary me-
tabolism, and present evidence that the hepatic ISR contributes
to the metabolic syndrome of obesity and insulin resistance
by translational upregulation of transcription factors involved in
carbohydrate and lipid metabolism.
RESULTS
The major determinant of ISR activity in liver is the ER stress-
activated kinase PERK, whose transient activation is difficult to
detect (Harding et al., 2001). To determine whether the ISR is
modulated by normal fluctuations in nutrient intake, we first mon-
itored two perdurable markers, BiP and XBP-1 mRNA, as surro-
gates for the UPR (and PERK activity). Feeding coincided with
a clear peak of these marker mRNAs (see Figure S1A available
online), suggesting that physiological ER stress is induced by
feeding, as predicted by previous studies (Dhahbi et al., 1997).
To gauge the transient phosphorylation of eIF2a, we fasted ani-
mals for 18 hr and refed them with normal (low-fat) and high-fat
chow. Levels of eIF2(aP)were barely detectable in liver after a 18hr
fast but increased 4 hr after feeding with ordinary chow and were
evenhigher inanimalsprovidedhigh-fat chow (FigureS1B).These
observations confirmed the previously noted (Ozcan et al., 2004)
correlation between physiological nutritional fluctuations and the
eIF2(aP)-dependent ISR in liver.
Selective Attenuation of the ISR in Liver
of Transgenic Mice
To study the potential significance of physiological levels of
eIF2(aP) in mouse liver, we sought to selectively interfere with
this phosphorylation event.Gadd34 (PPP1R15a) encodes a sub-
strate-specific regulatory subunit of a phosphatase that selec-
tively dephosphorylates eIF2a phosphoserine 51 (Novoa et al.,
2001). Gadd34 activity is tightly regulated at the transcriptional
level, and the gene is normally turned on by the ISR as part
of a negative feedback loop that terminates signaling (Novoa
et al., 2003); however, enforced expression of an active C-ter-
minal fragment of GADD34 is sufficient to dephosphorylate
eIF2(aP) and inhibit the ISR (Novoa et al., 2001). We exploited
this feature by expressing a GADD34 C-terminal fragment from
a liver-specific albumin (Alb) promoter in transgenic mice. The
GADD34 C-terminal active fragment (GC) was detected by im-
munoblot in liver lysates of transgenic Alb::GC mice (Figure 1A).
Expression of a single copy of the transgene attenuated feeding-
induced eIF2a phosphorylation, and two copies of the transgene
blocked phosphorylation even during severe ER stress in miceinjected with tunicamycin (Figure 1A). We conclude that the
Alb::GC transgene interferes with eIF2a phosphorylation in the
liver.
To estimate the consequences of the Alb::GC transgene on
the eIF2(aP)-mediated ISR and to generate a hypothesis for pos-
sible mechanisms, we established a reference database for the
activity of this pathway in the liver. PERK’s kinase activity can
be uncoupled from ER stress by fusion of the cytosolic PERK
kinase domain to an artificial dimerization domain (Fv2E) that
subordinates eIF2a phosphorylation to a soluble, otherwise inert
ligand, AP20187 (Lu et al., 2004b) (Figure S2A). In the absence of
ligand, the Fv2E-PERK chimera, expressed in the liver of trans-
genic mice (Ttr::Fv2E-Perk), is inert. However, following intraper-
itoneal (i.p.) injection of AP20187, the chimeric protein is acti-
vated (reflected by a shift in its mobility on SDS-PAGE) and
phosphorylates its substrate (Figure 1B). The Chop marker
gene was used to confirm the ligand and gene dose-dependent
activation of the ISR in the liver of Ttr::Fv2E-Perk mice (Figures
1C and 1D; Figure S2B), and a profile of genes thereby induced
was assembled using oligonucleotide hybridization microarrays
of liver mRNA. About half of the genes previously identified as
ISR targets in fibroblasts (Harding et al., 2003; Lu et al., 2004b)
were also induced in the liver of the transgenic mice following
injection of AP20187 ligand (Figure 1E; Table S1).
Next, we sought to determine whether the Alb::GC transgene,
which blocked eIF2a phosphorylation, interfered with expres-
sion of this hypothesized set of ISR genes in liver. As feeding
of a high-fat diet (HFD) promotes eIF2(aP) in the liver, we com-
pared the profile of genes expressed in the liver of wild-type
and Alb::GC mice fed high-fat or low-fat chow. As expected,
the genes constituting the hepatic ISR were expressed at higher
levels in the liver of HFD-fed wild-type mice. These diet-induced
differences in expression were attenuated by the Alb::GC trans-
gene (Figure 1E, bottom; same data in Table S2), suggesting that
the latter blocks signaling in a diet-induced ISR and that such
mice might constitute a useful tool for studying the role of this
pathway in metabolism.
Metabolic Profile of the ISR-Defective Alb::GC Mice
Apart from slight gene-dosage-dependent reduced body mass
(Figure 2A), adult Alb::GC mice were superficially indistinguish-
able fromwild-type littermates when fed a normal diet. However,
they were markedly impaired in defending blood glucose during
a fast (Figure 2B). This functional defect correlated with dimin-
ished hepatic glycogen reserves (Figures 2C and 2D) and atten-
uated glucose production in response to pyruvate loading (a
measure of gluconeogenesis) in fasted Alb::GC mice compared
with wild-type (Figure 2E).
A tendency toward fasting hypoglycemia may also explain the
high rates of perinatal attrition of Alb::GC transgenic mice (21 of
58 pups were found dead at postnatal day 1 in Alb::GC trans-
genic litters compared with 1 of 41 pups in the wild-type FVB/n
control; p < 0.05 by c2 test), a defect they share with homozy-
gous Eif2aS51A mice (Scheuner et al., 2001). Consistent with
these observations, Alb::GC mice also had enhanced glucose
tolerance in experimental surrogates of the fed state, as re-
flected in lower serum glucose levels following i.p. injection of
glucose (i.p. GTT, Figure 2F) and enhanced sensitivity to the
hypoglycemic effects of injected insulin (i.p. ITT, Figure 2G).Cell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc. 521
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eIF2a Blocks the Integrated Stress
Response in the Liver of Transgenic Mice
(A) Immunoblot of immunopurified GADD34
C-terminal fragment, phosphorylated eIF2a, total
eIF2a, and immunopurified PERK from liver ly-
sates of untreated (UT) and tunicamycin-injected
(Tm) nontransgenic (WT), heterozygous (GC/+),
and homozygous Alb::GC (GC/GC) transgenic
mice. The migration of inactive (PERK0) and active
(PERKP) PERK is indicated.
(B) Immunoblot of immunopurified PERK, phos-
phorylated eIF2a, and total eIF2a from liver lysates
of untreated (UT), AP20187-injected (AP), and
tunicamycin-injected (Tm) nontransgenic (WT)
and low-expressing Ttr::Fv2E-PERK transgenic
(Fv2E-PERK) mice. The inactive and active endog-
enous and transgenic Fv2E-PERK proteins are
labeled.
(C) Relative levels of CHOP mRNA in liver of low-
expressing Ttr::Fv2E-PERK transgenic mice 8 hr
after injection of AP20187. Shown are mean ±
SEM of a representative experiment (n = 3). Linear
regression analysis shows correlation factor r2 =
0.969.
(D) Relative levels of CHOP mRNA in liver after in-
jection of 0.2 mg/kg AP20187. Shown are mean ±
SEM (n = 4) of a representative experiment per-
formed in low- (p = 0.047 by one-way ANOVA)
and high-level-expressing lines of Ttr::Fv2E-
PERK transgenic mice (p = 0.006 by one-way
ANOVA).
(E) Expression profiling of integrated stress re-
sponse (ISR) target genes revealed by AP20187
treatment of Fv2E-PERK transgenic fibroblasts
(MEFs) with wild-type (Eif2aS/S) and mutant
(Eif2aA/A) genotypes (from Lu et al., 2004b). The
induction profile of the same genes in liver of
AP20187-injected Ttr::Fv2E-PERK transgenic
mice expressing low (n = 2) and high (n = 4) levels
of the transgene is shown below (data in Table S1).
The inset at the bottom left depicts the expression
level of a subset of these validated hepatic ISR tar-
get genes (those that are inducedmore than 2-fold by AP20187 expression in both Ttr::Fv2E-PERK transgenic lines) in high-fat diet (HFD)-fed nontransgenic (WT,
n = 2) and Alb::GC transgenic (GC/GC, n = 2) animals (data in Table S2).To analyze the ISR’s role in the context of nutrient excess, we
combined dietary manipulation with aurothioglucose injection,
thus overcoming the known resistance of FVB/n mice (the
background for the wild-type and transgenic mice studied
here) to diet-induced obesity (Hu et al., 2004). Between 6 and
21 weeks of age, the body weight of wild-type mice increased
2.43 ± 0.16-fold, and that of the Alb::GC transgenic mice in-
creased by 1.96 ± 0.08-fold (mean ± SEM, n = 12, p < 0.05)
(Figure 3A). The resulting glucose intolerance and insulin resis-
tance were also less in the Alb::GC mice compared to the wild-
type mice (Figures 3B–3D). Hepatic steatosis, a predictable
feature of obese wild-type male animals, was also significantly
lower in ISR-defective mice fed a HFD, as reflected in a lower
histochemical steatosis index of 0.8 ± 0.2 (mean ± SEM) in
Alb::GC versus 6.4 ± 0.2 in wild-type (n = 5, p < 0.005; see
also Figure 3E) (Kleiner et al., 2005) and lower liver tissue tri-
glyceride content: 10.72 ± 1.69 mg/gm in Alb::GC versus
21.34 ± 4.11 mg/gm in wild-type (mean ± SEM, n = 5, p <
0.05) (Figure 3F).522 Cell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc.The ISR Regulates Genes Involved
in Intermediary Metabolism
Two transcription factors are known to be activated by eIF2(aP):
ATF4, whose translation is paradoxically stimulated (Harding
et al., 2000; Lu et al., 2004a; Vattem and Wek, 2004), and
NF-kB, which undergoes derepression in the ISR (Jiang et al.,
2003; Deng et al., 2004). However, defective signaling to their
targets seemed unlikely to explain the altered hepatic gene ex-
pression program or the metabolic phenotype of the Alb::GC
mice (Harding et al., 2003) (Table S3). Therefore, in our search
for potential mediators of the metabolic effects of the ISR, we fo-
cused on other transcription factor-encoding genes that were
differentially expressed in wild-type and Alb::GC mice. At the
top of this list was peroxisome proliferator-activated receptor
g (PPARg; Pparg) (Table 1).
Originally identified as an activator of adipocyte differentiation
(reviewed in Rosen et al., 2000; Farmer, 2006), the nuclear recep-
tor PPARg has also been implicated in hepatic steatosis (Gavri-
lova et al., 2003; Schadinger et al., 2005). RT-PCR analysis
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liver of HFD-fedAlb::GCmice compared towild-type (Figure 4A).
Profiling also suggested a corresponding lower expression of
PPARg target genes involved in fatty acid synthesis in the
Alb::GC transgenic mice (Table 1), which was confirmed by
quantitative RT-PCR analysis of fatty acid synthetase (Fasn),
acetyl-CoA carboxylase a and b (Acaca and Acacb), and
stearoyl-CoA desaturase(Scd1) (Figures 4B–4E). This analysis
places Pparg downstream of the ISR in the liver and suggests
that its lower expression might contribute to reduced hepatic
steatosis in Alb::GC transgenic mice.
Translational Activation of C/EBP Proteins by the ISR
In adipocytes, CCAAT/enhancer-binding protein b (C/EBPb) and
the related C/EBPa isoform positively regulate PPARg expres-
sion through self-reinforcing feed-forward loops (reviewed in
Rosen et al., 2000; Farmer, 2006). Recent data suggest that
Figure 2. Fasting Hypoglycemia, Enhanced
Insulin Sensitivity, and Reduced Glycogen
Stores in the Liver of ISR-Defective Alb::GC
Transgenic Mice
(A) Body weight of nontransgenic (WT), heterozy-
gous (GC/+), and homozygous Alb::GC (GC/GC)
transgenic male mice as function of age (mean ±
SEM, n = 20).
(B) Blood glucose after fasting of adult male mice
of the indicated genotypes (mean ± SEM, n = 4,
*p < 0.05, #p < 0.01).
(C) Periodic acid-Schiff stain (glycogen) of repre-
sentative liver sections of fed and fasted mice of
the indicated genotypes.
(D) Liver glycogen content of fed and 18 hr-fasted
mice of the indicated genotypes (mean ± SEM,
WT n = 3, Alb::GC n = 5, *p < 0.05).
(E) Blood glucose levels as a function of time after
pyruvate loading in mice of the indicated geno-
types (mean ± SEM, n = 5, p < 0.001 by two-way
ANOVA).
(F) Blood glucose as a function of time after intra-
peritoneal (i.p.) injection of glucose in mice of
the indicated genotypes (mean ± SEM, n = 3,
p < 0.001 versus WT by two-way ANOVA).
(G) Blood glucose as a function of time (expressed
as a percent of level at t = 0) after i.p. injection of
insulin in mice of the indicated genotypes (mean ±
SEM, n = 4, p = 0.005 versus WT by two-way
ANOVA).
this relationship extends to the liver, as
Cebpb deletion reduces levels of PPARg2
mRNA and lipid accumulation in the liver
of obese mice (Millward et al., 2007;
Schroeder-Gloeckler et al., 2007). Fur-
thermore, C/EBP proteins also promote
glycogen synthesis and hepatic glucose
production (Wang et al., 1995; Liu et al.,
1999). These features are shared by the
ISR-defective Eif2aS51A mice (Scheuner
et al., 2001) and the Alb::GC mice here
(Figure 2 and Figure 3), prompting us to further probe the
relationship of the ISR to C/EBP expression.
Levels of C/EBPb protein weremore than 2-fold lower in nuclei
isolated from livers of Alb::GC mice than in nuclei isolated from
wild-type livers, and similar differences were observed in the
abundance of C/EBPa (Figures 5A and 5B). Given that the ISR
regulates its best known target, ATF4, translationally (Harding
et al., 2000; Lu et al., 2004a; Vattem andWek, 2004) and that iso-
form choice among C/EBP proteins has previously been shown
to be regulated translationally by the virally induced eIF2a kinase
PKR (Calkhoven et al., 2000), we decided to determine whether
the effects of the ISR on C/EBP protein levels also have a trans-
lation component.
The incorporation of [35S]methionine/cysteine into newly
synthesized C/EBPa and C/EBPb was measured by pulse label-
ing followed by immunoprecipitation. Activation of the ISR by
AP20187 in Fv2E-PERK-expressing chinese hamster ovary cellsCell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc. 523
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synthesized endogenous proteins (Figure 5C). This increase
occurred in the face of global repression of protein synthesis,
reflected here in the incorporation of label into the transcription
factor CREB (Figure 5C) and eIF2a (Figure 5D). As activated
Fv2E-PERK phosphorylates eIF2a without causing ER stress,
these findings suggest that the ISR can enhance C/EBP transla-
tion independently of other signaling pathways.
To extend these observations to a surrogate of the liver ISR,
a similar analysis was performed in HepG2 hepatoma cells
in which PERK was activated by thapsigargin. Incorporation of
label into newly synthesized C/EBPa and C/EBPb increased
2-fold within 30 min of treatment. Furthermore, the increase
in translation observed over 30 min of ISR induction in the thap-
sigargin-treated HepG2 cells was sustained in the face of tran-
scriptional inhibition by actinomycin D (Figure 5D), attesting to
its independence of new mRNA synthesis. The effectiveness of
actinomycin D in inhibiting mRNA synthesis is revealed by the
block to activation of a transcriptional target of the ISR, CHOP
(Figure 5D, inset).
Figure 3. Sustained Insulin Sensitivity and
Reduced Hepatosteatosis in ISR-Defective
Alb::GC Transgenic Mice on a High-Fat Diet
(A) Body weight of a cohort of 12 nontransgenic
(WT) and 12 Alb::GC transgenic mice over time
(mean ± SEM, p < 0.001 versus WT by two-way
ANOVA). High-fat diet (HFD) was instituted at
weaning (3 weeks), whereas the aurothioglucose
injection was introduced at 6 weeks of age.
(B) Blood glucose as a function of time after i.p.
injection of glucose in obese (HFD-fed) mice
of the indicated genotypes (mean ± SEM, n = 5,
p < 0.001 versus WT by two-way ANOVA).
(C) Plasma insulin of the samples in (B) (mean ±
SEM, n = 5, p < 0.001 versus WT by two-way
ANOVA).
(D) Blood glucose as a function of time after i.p.
injection of insulin in obese mice of the indicated
genotypes (mean ± SEM, n = 5, p < 0.001 versus
WT by two-way ANOVA).
(E) Hematoxylin and eosin (H&E) and oil red
O staining of representative liver sections of mice
of the indicated genotypes fed normal rodent
chow (LFD) or HFD.
(F) Triglyceride content of liver from wild-type
and Alb::GC transgenic mice fed LFD and HFD
(mean ± SEM, n = 5, *p < 0.05).
To determine whether attenuating the
ISR by Alb::GC expression affects trans-
lational induction of C/EBP in hepato-
cytes, we compared the incorporation
of labeled methionine/cysteine into C/
EBPb in untreated and thapsigargin-
treated primary hepatocytes explanted
from wild-type and Alb::GC transgenic
mice. Thapsigargin reproducibly enhanced
the incorporation of label into immuno-
purified C/EBPb in wild-type, but not
Alb::GC transgenic, hepatocytes (Figures
5E and 5F). As expected, attenuation of total protein synthesis by
thapsigargin was also less conspicuous in the Alb::GC trans-
genic sample. The rapid dedifferentiation of cultured primary
hepatocytes likely leads to an underestimate of the transgene’s
effect in vivo. Dedifferentiation may also account for our inability
to detect labeled C/EBPa in these samples.
The physiological significance of regulated expression of C/
EBP isoforms by the ISR is supported by the finding that genes
encoding key enzymes in hepatic glucose metabolism that are
known to be regulated by C/EBPs were reduced in the Alb::GC
transgenic mice. This relationship extended across a range of
physiological states from normal feeding (Figure 5G) to animals
in which diabetes mellitus had been induced by streptozotocin
injection (Figure 5H).
Expression profiling revealed that many ISR target genes were
induced to lower levels in the livers of transgenic mice from the
line expressingmore Fv2E-PERK (Figure 1E; Table S1). This find-
ing suggested negative feedback in the ISR, for example by
CHOP, a late downstream transcription factor induced by the
ISR (Harding et al., 2000) that inhibits conventional C/EBP target524 Cell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc.
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tiation (Batchvarova et al., 1995), or another transcriptional tar-
get of the ISR, ATF3, which inhibits ATF4 (Jiang et al., 2004).
To explore this suggestion of biphasic regulation of gene expres-
sion by the ISR, we injected Ttr::Fv2E-PERK transgenic animals
(of the lower-expressing line) with increasing amounts of the
AP20187 activator and measured mRNA levels in their livers
by RT-PCR. While CHOP, ATF3, and C/EBPb mRNA levels
increased monophasically with AP20187 dose, other genes
such as Pparg, Pck1 (Pepck), and other C/EBP target genes re-
sponded biphasically (Figure 6A). These observations suggest
that at lower levels of signaling, the ISR contributes positively
to the regulation of the same metabolic pathways that it inhibits
at unusually high, possibly pathological, levels of signaling.
DISCUSSION
By focusing on one branch of the UPR—the eIF2(aP)-mediated
ISR—and by restricting the genetic manipulation to a single
tissue—the liver—this study clarifies earlier work in mice with
pervasive alterations in the ER stress response that were ef-
fected by germline mutations in UPR pathway genes. Both the
hepatic ISR-defective Alb::GCmice described here and globally
ISR-defective homozygous Eif2aS51A mutant mice (Scheuner
et al., 2001) share a tendency toward fasting hypoglycemia
and reduced hepatic glycogen content. This argues that at least
some of the metabolic consequences of a defective ISR are
autonomous to the hepatocyte.
The aforementioned hepatic defect is well explained by lower
levels of C/EBPa and b protein in the liver of Alb::GC mice, as
both C/EBPa and b are known to positively regulate genes in-
volved in glycogen synthesis and hepatic glucose production
(Wang et al., 1995; Liu et al., 1999). Our findings argue that
ISR-mediated activation of C/EBPa and b can proceed by a
translational mechanism that is mobilized within minutes of in-
duction of eIF2a phosphorylation and functions independently
of newmRNA synthesis. Translational activation is aided by pre-
viously recognized transcriptional upregulation, which likely rein-
forces further C/EBP expression (Chen et al., 2004). In these
respects, the C/EBPs resemble the well-validated translational
target of the mammalian ISR, ATF4, and its yeast counterpart,
GCN4. However, the arrangement of conserved upstream
open reading frames in the C/EBPa and b genes suggests impor-
tant differences between the molecular mechanism by which
eIF2(aP) promotes their translation and that of ATF4/GCN4.
Two conserved upstream open reading frames specify regulated
translational reinitiation at the ATF4 (and GCN4) coding se-
quence when levels of phosphorylated eIF2a are high (Hinne-
busch and Natarajan, 2002; Lu et al., 2004a; Vattem and Wek,
2004). In the case of C/EBPa and b, our observations and those
of Calkhoven and colleagues (2000) are more readily explained
by a model whereby eIF2(aP) disfavors initiation at the single in-
hibitory short open reading frame conserved in their mRNAs and
favors initiation at one or more downstream AUGs. The mecha-
nism linking eIF2(aP) to regulated initiation at two consecutive
open reading frames remains to be resolved; however, the phe-
nomenon is not restricted to C/EBPa and b, as it is observed on
the ATF4 mRNA when the 50-most of the two upstream open
reading frames is deleted (see Figure 5B in Lu et al., 2004a).Our study also implicates the ISR in regulating lipid metabo-
lism in the liver, as Alb::GC mice accumulated less neutral lipid
in their livers when placed on a HFD. This alteration, too, appears
to be mediated by changes in gene expression, as levels of
enzymes involved in fatty acid synthesis were lower in the ISR-
defective transgenic mice compared with the wild-type. Lower
levels of PPARg might explain part of this defect, as a require-
ment for hepatic PPARg in the development of hepatic steatosis
has been noted recently (Gavrilova et al., 2003). C/EBP proteins
positively regulate PPARg expression (Millward et al., 2007; Rah-
man et al., 2007), which is consistent with a linear pathway from
eIF2(aP) to the C/EBP proteins and from there to PPARg (Fig-
ure 6B). Furthermore, the ISR-defective Alb::GC transgenic
mice gain significantly less weight when placed on a HFD. While
a detailed understanding of the physiological mechanisms
awaits further studies, the pervasive role of eIF2(aP) in regulating
genes involved in glycogenesis and lipid synthesis is consistent
with the idea that impaired conversion of ingested nutrients
to their storage forms limits weight gain in these ISR-defective
animals.
In cultured cells, transient activation of the ISR promotes
survival and adaptation whereas unremitting signaling promotes
cell death (Rutkowski et al., 2006). The observations made here
provide an interesting parallel in terms of intermediary metabo-
lism in the liver: low-level signaling in the ISR (as observed under
physiological circumstances) promotes expression of genes
involved in glycogen synthesis, gluconeogenesis, and fatty
acid synthesis, whereas higher levels of signaling repress the ex-
pression of the same genes. These findings might be explained
by differential responsiveness of the ISR’s effectors to signaling
at different intensities, as proposed by Rutkowski et al. (2006).
CHOP, ATF3, and C/EBPb mRNA levels increase monophasi-
cally with signal strength, but expression of downstream C/
EBP target genes declines at high levels of ISR activity (Fig-
ure 6A). CHOP-mediated inhibition of C/EBP proteins (Ron and
Habener, 1992) and direct repression of PEPCK by ATF3 (Al-
len-Jennings et al., 2002) could contribute to the declining limb
of the biphasic relationship between strength of ISR signal and
downstream target gene expression.
Biphasic regulation of enzymes involved in fatty acid biosyn-
thesis may also explain an apparent discrepancy between this
study, in which signaling in the hepatic ISR is shown to promote
steatosis in mice fed a HFD, and the observation that global
Gcn2 deletion predisposes mice fed a leucine-deficient diet to
steatosis (Guo and Cavener, 2007). Perhaps leucine deficiency
is associated with levels of ISR signaling that repress lipid syn-
thesis in wild-type mice but fail to achieve this level in Gcn2/
mice. Alternatively, the lower levels of amino acid transporters
noted in ISR-defective cells (Harding et al., 2003) may further
reduce hepatic uptake of leucine and sensitize amino acid-
deprivedGcn2/mice to fatty liver by further reducing the build-
ing blocks for lipoprotein synthesis and thereby lipid export.
It has previously been reported that a partial compromise in
downstream signaling in the IRE1 branch of the UPR (effected
by haploid insufficiency for Xbp1) accentuates insulin resistance
and promotes glucose intolerance in obese mice (Ozcan et al.,
2004) and that protein and chemical chaperones that reduce
ER stress in insulin target tissues ameliorate that phenotype
(Ozawa et al., 2005; Ozcan et al., 2006). Our study suggestsCell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc. 525
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The ISR and Intermediary MetabolismTable 1. List of Genes Discordantly Regulated by High-Fat Feeding in Wild-Type and Alb::GC Mice
Name Description Entrez Gene
Expression Level
HFD Induction (Fold)
% of WT in
GC HFD
WT Alb::GC
LFD HFD LFD HFD
WT
HFD/LFD
Alb::GC
HFD/LFD
Transcription Factors
Pparg peroxisome
proliferator-activated
receptor gamma
19016 0.97 ± 0.28 4.05 ± 0.04 0.68 ± 0.71 0.25 ± 0.11 4.18 ± 1.03 0.37 ± 0.13 6 ± 2
Crsp6 cofactor required
for Sp1
transcriptional
activation, subunit 6
234959 0.69 ± 0.13 2.29 ± 0.51 1.02 ± 0.33 0.65 ± 0.22 3.30 ± 0.09 0.63 ± 0.01 28 ± 3
Jarid1d jumonji, AT rich
interactive domain 1D
(Rbp2-like)
20592 0.49 ± 0.14 1.38 ± 1.14 1.74 ± 3.07 0.45 ± 0.35 2.84 ± 1.01 0.26 ± 0.12 32 ± 1
Klf13 Kru¨ppel-like factor 13 50794 0.65 ± 0.27 4.20 ± 0.19 0.87 ± 0.16 1.41 ± 0.63 6.44 ± 1.95 1.61 ± 0.33 33 ± 11
Ppara peroxisome
proliferator-activated
receptor alpha
19013 0.83 ± 0.13 5.41 ± 0.29 0.61 ± 0.26 1.82 ± 1.35 6.51 ± 0.57 2.99 ± 0.59 34 ± 18
Sox-4 SRY-box containing
gene 4
20677 0.86 ± 0.45 2.93 ± 0.60 0.67 ± 0.02 1.02 ± 0.53 3.41 ± 0.81 1.54 ± 0.61 35 ± 8
Nfic nuclear factor I/C 18029 0.47 ± 0.05 3.80 ± 0.38 0.59 ± 0.03 1.67 ± 0.35 8.04 ± 0.01 2.81 ± 0.40 44 ± 4
Cphx cytoplasmic
polyadenylated
homeobox
105594 0.28 ± 0.37 1.55 ± 0.62 0.13 ± 0.04 0.69 ± 0.22 5.49 ± 2.81 5.24 ± 0.12 44 ± 3
Akna AT-hook transcription
factor
100182 0.39 ± 0.24 1.69 ± 0.48 0.60 ± 0.14 0.79 ± 0.25 4.33 ± 1.79 1.31 ± 0.35 47 ± 6
Mxd3 Max dimerization
protein 3
17121 0.29 ± 0.06 1.10 ± 0.09 0.54 ± 0.23 0.56 ± 0.52 3.84 ± 0.44 1.04 ± 0.32 51 ± 31
Mef2a myocyte enhancer
factor 2A
17258 0.27 ± 0.02 1.73 ± 0.19 0.51 ± 0.81 0.96 ± 0.32 6.39 ± 0.29 1.88 ± 1.33 55 ± 10
Klf3 Kru¨ppel-like factor 3
(basic)
16599 0.74 ± 0.04 1.74 ± 0.08 0.93 ± 0.04 1.04 ± 0.17 2.37 ± 0.01 1.12 ± 0.12 60 ± 6
Nfkb2 NF-kappaB2/p100 18034 0.27 ± 0.03 3.27 ± 0.10 0.32 ± 0.00 1.98 ± 0.36 11.93 ± 0.81 6.27 ± 0.97 61 ± 8
Bach2 BTB and CNC
homology 2
12014 0.52 ± 0.62 1.90 ± 0.18 0.50 ± 0.11 1.16 ± 0.39 3.66 ± 2.73 2.29 ± 0.23 61 ± 12
Zkscan1 zinc finger
with KRAB and SCAN
domains 1
74570 0.73 ± 0.14 1.60 ± 0.05 0.98 ± 0.04 1.11 ± 0.14 2.20 ± 0.33 1.13 ± 0.09 69 ± 6
Carbohydrate Metabolism
Pdha2 pyruvate
dehydrogenase E1
alpha 2
18598 0.16 ± 0.02 0.37 ± 0.26 0.23 ± 0.14 0.14 ± 0.06 2.26 ± 1.01 0.61 ± 0.07 39 ± 7
Pdk3 pyruvate
dehydrogenase
kinase, isoenzyme 3
236900 0.33 ± 0.02 0.87 ± 0.09 0.38 ± 0.05 0.37 ± 0.06 2.61 ± 0.14 0.98 ± 0.03 42 ± 3
Mdh2 malate
dehydrogenase 2,
NAD (mitochondrial)
17448 0.75 ± 0.18 1.91 ± 0.10 0.64 ± 0.04 1.11 ± 0.04 2.54 ± 0.42 1.72 ± 0.04 58 ± 1
Agl amylo-1,
6-glucosidase, 4-alpha-
glucanotransferase
77559 0.85 ± 0.13 1.85 ± 0.07 0.71 ± 0.04 1.09 ± 0.09 2.17 ± 0.23 1.54 ± 0.03 59 ± 2
Ppp2r5e protein phosphatase
2, regulatory
subunit B (B56),
epsilon
26932 0.43 ± 0.03 2.57 ± 0.19 0.45 ± 0.35 1.52 ± 0.40 6.00 ± 0.02 3.37 ± 1.17 59 ± 10526 Cell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc.
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Name Description Entrez Gene
Expression Level
HFD Induction (Fold)
% of WT in
GC HFD
WT Alb::GC
LFD HFD LFD HFD
WT
HFD/LFD
Alb::GC
HFD/LFD
Ppp1r1a protein phosphatase 1,
regulatory (inhibitor)
subunit 1A
58200 0.60 ± 0.11 1.39 ± 0.04 0.79 ± 0.10 0.84 ± 0.20 2.33 ± 0.32 1.07 ± 0.09 61 ± 11
Gyg glycogenin 27357 0.68 ± 0.09 1.99 ± 0.12 0.31 ± 0.61 1.26 ± 0.20 2.93 ± 0.18 4.11 ± 4.48 63 ± 6
Pcx pyruvate carboxylase 18563 0.72 ± 0.07 1.90 ± 0.08 0.72 ± 0.11 1.19 ± 0.08 2.64 ± 0.17 1.66 ± 0.20 63 ± 2
Pklr pyruvate kinase
liver and red blood
cell
18770 0.66 ± 0.09 1.67 ± 0.10 0.99 ± 0.15 1.11 ± 0.06 2.53 ± 0.25 1.12 ± 0.07 66 ± 3
Gbe1 glucan (1,4-alpha-),
branching
enzyme 1
74185 0.60 ± 0.01 2.07 ± 0.17 0.71 ± 0.01 1.40 ± 0.14 3.43 ± 0.22 1.96 ± 0.15 68 ± 1
Suclg2 succinate-coenzyme
A ligase, GDP-forming,
beta subunit
20917 0.73 ± 0.02 1.59 ± 0.03 0.84 ± 0.06 1.13 ± 0.04 2.17 ± 0.02 1.34 ± 0.05 71 ± 1
Lipid Metabolism
Scd1 stearoyl-coenzyme A
desaturase 1
20249 0.81 ± 0.19 3.43 ± 0.11 1.18 ± 0.25 0.90 ± 0.10 4.24 ± 0.77 0.76 ± 0.06 26 ± 2
Fasn fatty acid synthase 14104 0.85 ± 0.25 2.26 ± 0.09 0.98 ± 0.08 0.88 ± 0.06 2.66 ± 0.58 0.90 ± 0.01 39 ± 1
Gpd2 glycerol phosphate
dehydrogenase 2,
mitochondrial
14571 0.86 ± 0.29 1.86 ± 0.05 0.89 ± 0.03 0.84 ± 0.24 2.17 ± 0.58 0.95 ± 0.21 45 ± 10
Lpl lipoprotein lipase 16956 0.66 ± 0.15 1.96 ± 0.68 0.83 ± 0.36 0.93 ± 0.48 2.95 ± 0.27 1.13 ± 0.06 48 ± 6
Olah oleoyl-ACP hydrolase 99035 0.12 ± 0.00 0.34 ± 0.07 0.12 ± 0.01 0.17 ± 0.05 2.82 ± 0.47 1.43 ± 0.27 50 ± 4
Acaca acetyl-coenzyme A
carboxylase alpha
107476 0.62 ± 0.43 1.82 ± 0.30 0.71 ± 0.02 1.11 ± 0.19 2.94 ± 1.12 1.58 ± 0.20 61 ± 0
Gyk glycerol kinase 14933 0.53 ± 0.04 1.84 ± 0.06 0.69 ± 0.16 1.16 ± 0.00 3.46 ± 0.16 1.68 ± 0.35 63 ± 2
Hadh hydroxyacyl-
coenzyme A
dehydrogenase
15107 0.32 ± 0.16 2.78 ± 0.02 0.25 ± 0.02 1.87 ± 0.44 8.57 ± 3.53 7.45 ± 0.94 67 ± 14
Translation, Amino Acid Import, and Metabolism
Eif3s6 eukaryotic translation
initiation factor 3,
subunit 6
16341 0.42 ± 0.11 1.03 ± 0.18 0.81 ± 0.92 0.33 ± 0.11 2.43 ± 0.14 0.41 ± 0.21 32 ± 4
Aoc3 amine oxidase,
copper containing 3
11754 0.21 ± 0.04 0.67 ± 1.23 0.55 ± 1.35 0.19 ± 0.05 3.17 ± 3.17 0.35 ± 0.42 29 ± 26
Pgd phosphogluconate
dehydrogenase
110208 0.91 ± 0.18 2.04 ± 0.05 1.00 ± 0.11 0.82 ± 0.02 2.24 ± 0.35 0.82 ± 0.06 40 ± 0
Rps18 ribosomal protein
S18
20084 0.61 ± 0.11 2.39 ± 2.01 1.03 ± 0.09 0.96 ± 0.08 3.91 ± 1.77 0.93 ± 0.01 40 ± 22
RPL39L ribosomal protein
L39-like
68172 0.50 ± 0.20 1.32 ± 0.71 0.12 ± 0.03 0.75 ± 0.03 2.65 ± 0.26 6.33 ± 1.31 57 ± 23
Slc12a1 solute carrier
family 12, member 1
20495 0.16 ± 0.10 1.80 ± 0.07 0.57 ± 0.84 1.25 ± 1.38 11.52 ± 5.41 2.22 ± 0.37 70 ± 53
Tph1 tryptophan
hydroxylase 1
21990 0.44 ± 0.14 1.40 ± 0.34 1.25 ± 0.55 0.99 ± 0.43 3.22 ± 0.23 0.79 ± 0.00 71 ± 10
Shown are genes inducedR2-fold by high-fat diet (HFD) feeding in wild-type (WT) mice and reduced by at least 25% in HFD-fed Alb::GC transgenic
mice compared to HFD-fedWT. ‘‘HFD induction’’ is the ratio of the hybridization signals in HFD-fed versus low-fat diet (LFD)-fed mice. ‘‘% ofWT in GC
HFD’’ is the percentage of the signal of HFD-fed WT observed in HFD-fed Alb::GC (GC) mice. The mean ± standard deviation of the expression level
(see Experimental Procedures) inWT andAlb::GC from two independent mice is shown. The uppermost cluster is a list of genes encoding transcription
factors that satisfy the above criteria but are also inducedR2-fold in AP20187-injected (0.2 mg/gm body weight) high-expressing Ttr::Fv2E-PERK (line
#30) transgenic mice. The three clusters below list genes involved in carbohydrate, lipid, and amino acid metabolism that satisfy the above criteria.Cell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc. 527
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The ISR and Intermediary Metabolisma parallel process operating in hepatocytes, whereby heightened
activity of the ISR and its downstream target genes contributes
to the link between (physiological) ER stress and the metabolic
syndrome of obesity and diabetes. In regard to intermediary me-
tabolism, signaling by IRE1 and the ISR proceed in parallel, and
neither seems to dominate the metabolic phenotype. This is ex-
emplified by observations that insulin signaling to its proximal
targets is not obviously affected by the ISR perturbation (data
not shown), whereas such a defect is predicted in a system dom-
inated by IRE1 signaling. Though loss of translational control in
the ISR-defective state leads to more IRE1 signaling, which im-
pairs insulin signaling, our study suggests that the net effect of
a compromised ISR is to ameliorate the metabolic phenotype
in mice exposed to nutrient excess.
It is interesting to speculate on the evolutionary origins of the
link between the ISR and intermediary metabolism. Gene knock-
out experiments show that in most mammalian tissues, the ER
stress-inducible kinase PERK dominates ISR activity (Harding
et al., 2001). However, the GCN2-posessing ancestor in which
PERK first evolved already had in place a gene expression
program responsive to eIF2(aP) thatmodulated intermediaryme-
tabolism (Hinnebusch andNatarajan, 2002).Wepropose that this
preexisting link was co-opted by PERK to coordinate intermedi-
ary metabolism with nutritionally entrained variation in load of
unfolded client proteins that enter the ER of insulin-responsive
Figure 4. Reduced Expression of PPARg and Its Tar-
get Lipogenic Enzymes in the Liver of ISR-Defective
Alb::GC Transgenic Mice on a High-Fat Diet
Relative levels of PPARg (A), FASN (B), ACACb (C), ACACa (D),
and SCD1 (E) mRNA in the liver of nontransgenic (WT) and
Alb::GC transgenic mice in the fasted state or fed a low-fat
diet (LFD)orhigh-fat diet (HFD) (mean±SEM,n=3–4, *p<0.05).
tissues. This model is supported by the observation
that yeasts, which lack PERK, also use ER activity
as a proxy for nutrient availability but effect this by
IRE1 signaling (Schroder et al., 2000; Patil et al.,
2004). Presumably, under conditions of limited nu-
trient availability, this fine tuning of intermediaryme-
tabolism by physiological levels of ER stress signal-
ing is adaptive; however, in the presence of excess
nutrients, the ISR’s contributions to lipid synthesis
andhepaticglucoseproductionare counterproduc-
tive and promote glucose intolerance and liver stea-
tosis. Time will tell whether this example of failure of
homeostasis can be exploited therapeutically, by
targeting distinct facets of the ISR with inhibitors.
EXPERIMENTAL PROCEDURES
Transgenic Mice
A 2.3 kb mouse albumin enhancer/promoter fragment was
used to drive expression of hamster GADD34 (aa 292–590)
in the Alb::GC transgene. Two transgenic lines, #14 and #16,
were established in the FvB/n strain. These lines exhibited
similar sensitivity to fasting hypoglycemia, and the higher-ex-
pressing line, #14, was used in subsequent studies.
As we were unable to obtain lines expressing Fv2E-PERK
using the Alb promoter, the transthyretin (Ttr) promoter was
used instead to produce six Ttr::Fv2E-Perk transgenic lines in FvB/n, two of
which, expressing the protein at different levels (#30 ‘‘high’’ and #58 ‘‘low’’;
Figure S2B), were selected for further study. For the experiment reported in
Table S3, the low-expressing Ttr::Fv2E-Perk transgenic line (#58) was bred
into the Atf4 knockout strain, the derivative compound heterozygous mice
(in the mixed FvB/n; Swiss Webster background) were backcrossed to the
Atf4+/ parental stock, and Ttr::Fv2E-PERK-positive siblings with Atf4+/+ and
Atf4/ genotypes were analyzed.
Animal Experiments
All experiments in mice were approved by the New York University School of
Medicine Institutional Animal Care and Use Committee. Because of their
enhanced susceptibility to the metabolic consequences of nutrient excess,
male mice were used. These animals were maintained on low-fat diet (LFD)
containing 12% fat or high-fat diet (HFD) containing 60% fat (Research Diets
#D12492) with 12 hr light and dark cycles.
To induce hypoinsulinemic diabetes, streptozotocin (100 mg/kg, Sigma)
freshly dissolved in citrate buffer (pH 4.5) was injected i.p. into 10- to 12-
week-old mice on 2 consecutive days.
For diet-induced obesity, aurothioglucose (0.5 mg/g, Schering-Plough) was
injected i.p. as a single dose into 6-week-old mice.
For the glucose tolerance test, mice were fasted overnight (14 hr) and
injected i.p. with a glucose solution (2 g/kg). For the insulin tolerance test,
mice were fasted for 4 hr and injected i.p. with human insulin (0.75 mU/kg,
Eli Lilly). For pyruvate loading, mice were fasted for 16 hr and injected i.p.
with 1.5 g/kg sodium pyruvate. Blood glucose and plasma insulin concentra-
tions were measured from tail blood using a OneTouch Ultra glucometer
(Johnson & Johnson) and a rat/mouse insulin ELISA kit (Linco Research),
respectively.528 Cell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc.
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The ISR and Intermediary MetabolismFigure 5. Translational Upregulation of C/EBPa and b by the ISR
(A) Immunoblot of C/EBPa, C/EBPb, and CREB (as a loading control) in nuclear extract of livers of individual animals of the indicated genotypes. The ratio of
C/EBP to CREB signal in each sample is indicated.
(B) Graphic presentation of the data in (A) (mean ± SEM, n = 4, *p < 0.05).
(C) Autoradiograph of [35S]methionine/cysteine-labeled endogenous proteins immunoprecipitated from Fv2E-PERK transgenic CHO cells after a 30 min labeling
pulse in the presence of the indicated concentrations of AP20187 (AP). The relative signal level in each sample is indicated below the panel.
(D) Autoradiograph of [35S]methionine/cysteine-labeled endogenous proteins immunoprecipitated from HepG2 cells after a 30 min labeling pulse in the presence
of the indicated concentrations of thapsigargin (Tg) and/or actinomycin D (ActD). The inset is an autoradiogram of CHOP immunoprecipitated from cells exposed
to Tg for 6 hr and actinomycin D for 2 hr before the labeling pulse.
(E) Autoradiogram of an experiment identical in design to that in (D), performed on primary hepatocytes obtained from wild-type and Alb::GC mice. The upper
panel showsmetabolically labeled immunopurified C/EBPb; the lower panel showsmetabolically labeled proteins in the cell lysate. The ratio of label incorporated
into C/EBPb versus total protein, normalized to the untreated WT sample, is reported below. Shown is a typical experiment reproduced three times.
(F) Plot of the ratio of labeled C/EBPb to total protein in all experiments performed on untreated and Tg-treated primary hepatocytes from wild-type and Alb::GC
transgenic mice (mean ± SEM in arbitrary units, n = 3, *p < 0.05).
(G) Relative levels of glucokinase (GK) mRNA in liver of fasted and fed nontransgenic (WT) and Alb::GC transgenic mice (mean ± SEM, n = 3, *p < 0.05).
(H) Relative levels of PEPCKmRNA in liver of untreated (UT) and streptozotocin (STZ)-injected animals of the indicated genotypes (mean ± SEM, n = 3, *p < 0.05).
The inset at right shows morning nonfasted blood glucose of the same animals.Cell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc. 529
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The ISR and Intermediary MetabolismTo determine liver glycogen content, livers (100–150 mg) were digested in
0.3 ml of 30% KOH for 30 min at 100C, followed by addition of 0.1 ml of
20% NaSO4 and 0.8 ml of ethanol. Macromolecules containing glycogen
were precipitated by centrifugation (20,000 3 g, 10 min) and washed with
70% ethanol. The pellets were hydrolyzed in 0.5 ml of 4 N H2SO4 for 10
min at 100C and neutralized by 0.5 ml of 4 N NaOH. To measure glucose
concentration, 5 ml of the sample supernatant was added in a glucose (HK)
assay reagent (Sigma). Liver glycogen concentration was determined by
comparison with a standard curve constructed by glycogen from oyster
type II (Sigma).
Triglyceride content of liver tissue was measured enzymatically (L-Type TG
H test,Wako Pure Chemical Industries) on lipids extracted from tissue samples
with chloroform:methanol (2:1 mix).
Histological Analysis
Livers from animals perfused with 10% paraformaldehyde were fixed in the
same, paraffin embedded, sectioned in 5 mmslices, and stainedwith hematox-
ylin and eosin or periodic acid-Schiff (PAS). Oil red O was used to stain neutral
Figure 6. Biphasic Regulation of Genes Involved in Intermediary
Metabolism by the ISR
(A) Relative levels of the indicated mRNAs in liver of Ttr::Fv2E-PERK transgenic
mice 8 hr after i.p. injection of the indicated doses of AP20187 (AP). The com-
pletedatasetandstatistical analysis for thisexperiment ispresented inTableS5.
(B) Summary of interactions between components of the ISR regulating
intermediary metabolism.530 Cell Metabolism 7, 520–532, June 2008 ª2008 Elsevier Inc.lipids in frozen liver sections. Hepatic steatosis was assessed in three cate-
gories—grade, location, and microvesicularity—and a composite score was
obtained (based on Kleiner et al., 2005).
RNA Analysis
Livers were snap frozen in liquid nitrogen, and total RNA was isolated using
RNA-STAT60 (Tel-Test) and an RNeasy Mini Kit (QIAGEN). For gene expres-
sion profiling, total RNA was fluorescently labeled and hybridized to Affymetrix
mouse genome 430A 2.0 GeneChip or Affymetrix murine genome U74Av2
GeneChip under standard conditions. Primary image analysis of the arrays
was performed using GeneChip 3.2 software (Affymetrix). The raw data from
the hybridization experiments were analyzed by GeneSpring GX (Agilent Tech-
nologies). The raw signal from each gene was normalized to the mean strength
of all genes from the same chip to obtain the normalized signal strength. Then,
to allow visualization of all data on the same scale for subsequent analysis, the
normalized signal strength of each gene was divided by the median signal
strength for that gene among all samples to obtain the normalized expression
level.
Quantitative RT-PCR was performed with the iScript One-Step RT-PCR kit
using the MyiQ single-color real-time PCR detection system (Bio-Rad Labora-
tories). All PCR reactions were performed in duplicate or triplicate, and PCR
products were subjected to a melting curve analysis. The abundance of
specific mRNAs was determined by comparison with a standard curve con-
structed by serial dilution of the sample and normalized to b-actin. Primers
used for PCR reactions are listed in Table S4.
Cell Culture
HepG2 cells were cultured in regular DMEM supplemented with 10% Fetal-
Clone II serum (Hyclone) and penicillin-streptomycin. CHO-KI cells were
grown in Ham’s F12 supplemented with 10% FetalClone II serum and penicil-
lin-streptomycin.
Primary hepatocytes were isolated from wild-type and Alb::GC mice, cul-
tured on type I collagen-coated plates in Waymouth’s medium supplemented
with 0.1 nM insulin, andmetabolically labeled as described previously (Oyado-
mari et al., 2006).
Protein Analysis
PERK and GADD34 were detected in liver lysates by immunoprecipitation
followed by immunoblotting as described or by direct immunoblotting of the
lysates to detect phosphorylated and total eIF2a as described previously
(Harding et al., 2001). C/EBPa, C/EBPb, and CREB were blotted in a nuclear
extract prepared from liver. Antibodies for immunoprecipitation for GADD34
and PERK and immunoblotting procedures for eIF2a, GADD34, PERK, C/
EBPa, C/EBPb, and CREB have been described previously (Batchvarova
et al., 1995; Harding et al., 2001; Novoa et al., 2001). Phosphorylated eIF2a
was detected using BioSource Ab #44-728G lot #0201.
The translation of C/EBPa, C/EBPb, ATF4, CREB, and eIF2a was measured
by pulse labeling and immunoprecipitation in Fv2E-PERK-expressing CHO
cells (Lu et al., 2004a), HepG2 cells, and primary hepatocytes. For metabolic
labeling, cells were switched to methionine and cysteine minus DMEM with
10% dialyzed fetal calf serum 5 min before addition of TRAN35S-LABEL (MP
Biomedicals) at 400 mCi/ml for 30 min.
Statistical Analysis
All results are expressed as means ± SEM. Unpaired two-tailed Student’s t
tests were performed to determine p values for paired samples, and two-
way ANOVA with repeat measurements was performed to analyze measure-
ments obtained by time course.
ACCESSION NUMBERS
The complete data set for the data reported herein has been submitted to the
NCBI GEO database (http://www.ncbi.nlm.nih.gov/geo/) with the accession
numbers GSE11116 and GSE11210.
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